Ozanimod trail results

A phase III trial comparing ozanimod and Avonex as a treatment for people with relapsing MS, found that the drug was more successful at reducing the relapse rate - though no figures are given. Ozanimod didn't show any significant difference in slowing build-up of disability

Gilenya effect on relapses

A study of people taking Gilenya (fingolimod) found the drug reduced relapses by 75% over the first two years. People for whom it was their first disease modifying drug saw a bigger reduction (85%) than those who had had a previous treatment (67%).

Neurological Alliance manifesto

The Neurological Alliance has put together a list of five issues that it wants General Election candidates to address: access to specialist care; support from primary care professionals; research into new and better treatments; shared decision making and equitable access to treatments; mental health needs of people with neurological conditions

Fampridine granted full licence

Based on the results of the ENHANCE trial into the long-term benefits of fampridine (Fampyra), the European Commission has granted a standard marketing authorization. The research addressed the issues that led to fampridine previously only having a conditional licence. The change of licence is unlikely to have an effect on the decision by NICE that fampridine is not a cost effective treatment

Case of PML in Ocrevus

Someone in Germany who was taking Ocrevus (ocrelizumab) has been diagnosed with the brain infection, PML. They had previously been taking Tysabri (natalizumab) for three years. The cause of PML in this case is unclear and being investigated